Regent Pacific (or the “Group”) is a Hong Kong-based investment company holding ground-breaking corporate and strategic investments focused on the healthcare and life sciences sectors.
The Group’s principal investment is Plethora Solutions Holdings plc (“Plethora”), a wholly-owned subsidiary. Plethora is a specialty pharmaceutical company that is focussed on the commercialisation of its product Fortacin™ – the first EU-approved topical prescription treatment for premature ejaculation – as its core product. Fortacin™ was commercially launched across key European markets (France, Germany, Italy, Spain and Portugal in early 2018, the United Kingdom in early 2019 and Greece in Q4 2019) through its European commercial partner, Recordati S.p.A. ("Recordati"). Recordati plans to launch Fortacin™ in Romania later this year and it may be rolled out in other European countries over the coming years, subject to the status of the novel coronavirus disease pandemic and the anticipated switch of Fortacin™ to “over-the-counter” status from prescription.
In parallel with the European roll out efforts of Fortacin™, the Group has further progressed regulatory approvals with its key partners in Asia, being: (i) Wanbang Pharmaceutical Marketing and Distribution Co., Ltd., a wholly-controlled company of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., in respect of the rights to commercialise Fortacin™ in The People’s Republic of China (the "PRC"), in respect of which progress has been made with the National Medical Products Adminstration regarding submission of the investigational new drug application for clinical trial approval; and (ii) Orient EuroPharma Co., Ltd., a company registered in Taiwan, in respect of the rights to commercialise Fortacin™ in other select Asian countries.
In addition, Plethora continues to work through the approval process with The Food and Drug Administration of the United States (the “US”) in respect of its efforts to commercialise Fortacin™ in the US which, together with the PRC, is its potentially most significant markets.
Discussions are ongoing with new potential commercial partners with regards to “out-licensing” Fortacin™ in other key markets including the Asia Pacific region, Middle East, Latin America, North America and sub-Sahara Africa.
Regent Pacific has been listed on The Stock Exchange of Hong Kong Limited since May 1997. The company has a strong track record of investments and has returned approximately US$298 million to shareholders since its IPO.